<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134330">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01696279</url>
  </required_header>
  <id_info>
    <org_study_id>SPD405-207</org_study_id>
    <nct_id>NCT01696279</nct_id>
  </id_info>
  <brief_title>A Comparison of Lanthanum Carbonate and Calcium Carbonate in Children</brief_title>
  <official_title>A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate Using a Crossover Design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 Years to &lt;18 Years With Chronic Kidney Disease on Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Chile: Instituto de Salud PÃºblica de Chile</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Romania: Comisia Nationala de Bioetica a Medicamentului si Dispozitivelor Medicale</authority>
    <authority>Czech Republic: Statni ustav pro kontrolu leciv</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To provide information about the safety and efficacy of lanthanum carbonate in children
      compared to standard treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of subjects achieving age-specific Kidney Disease Outcomes Quality Initiative (KDOQI) targets for serum phosphorus</measure>
    <time_frame>8 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum phosphorus at up to 8 weeks</measure>
    <time_frame>Baseline and up to 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Calcium Levels at up to 8 weeks</measure>
    <time_frame>Baseline and up to 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Calcium-Phosphorous Product at up to 8 Weeks</measure>
    <time_frame>Baseline and up to 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Lanthanum Carbonate</measure>
    <time_frame>over 48 hours post-dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve from time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Lanthanum Carbonate</measure>
    <time_frame>over 48 hours post-dose on Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum phosphorus at up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Calcium Levels at up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Calcium-Phosphorous Product at up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Bone Alkaline Phosphatase (ALP) at Up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Tartrate-Resistant Acid Phosphatase (TRAP) at Up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Osteocalcin levels at Up to 10</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fibroblast Growth factor 23 (FGF-23) Levels at Up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Parathyroid Hormone (PTH) Levels at Up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Sclerostin Levels at Up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fetuin-A Levels at Up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Height at up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Weight at Up to 10 Months</measure>
    <time_frame>Baseline and up to 10 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hyperphosphataemia in Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Lanthanum Carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium Carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate</intervention_name>
    <description>Subjects will receive Lanthanum carbonate orally at a total daily dose of 1500 mg to 3000 mg divided equally between three meals.</description>
    <arm_group_label>Lanthanum Carbonate</arm_group_label>
    <other_name>Fosrenol, SPD405</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium carbonate</intervention_name>
    <description>Subjects will receive Calcium carbonate orally at a total daily dose taken by the subject prior to starting the study or equivalent.  For new subjects, dosing will be based on standard clinical practice.  The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500mg is reached.</description>
    <arm_group_label>Calcium Carbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 10 years to less than 18 years of age at the time of consent

          2. Serum phosphorus levels as follows:

               -  Age less than 12 years: Serum phosphorus greater than 6.0 mg/dL (1.94 mmol/L)

               -  Age 12 years and older: Serum phosphorus greater than 5.5 mg/dL (1.78 mmol/L)

        Exclusion Criteria:

          1. Unable to eat semi-solid foods or on Total Enteral Alimentation

          2. Serum PTH greater than 700 pg/mL

          3. Serum calcium greater than 10.2 mg/dL (2.54 mmol/L)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Haffner, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Call Centre</last_name>
    <phone>+1 866 842 5335</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Infantil Del Rinon S.R.L</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Rodriguez</last_name>
      <phone>0381156449317</phone>
      <email>paula_rod@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Susana C Miceli, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Ninos Ricardo Gutierrez</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1425EFD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Liern</last_name>
      <phone>00541541461822</phone>
    </contact>
    <investigator>
      <last_name>Graciela Vallejo, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital For Active Treatment In Pediatrics-Sofia Nephrology And Haemodialysis Clinic</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Luis Calvo Mackenna</name>
      <address>
        <city>Santiago</city>
        <zip>7500539</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Ibacache</last_name>
      <email>mjibacache@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Cano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Sotero del Rio</name>
      <address>
        <city>Santiago</city>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Sandretti</last_name>
      <phone>+562 2576 2617</phone>
      <email>asandretti@ssmso.cl</email>
    </contact>
    <investigator>
      <last_name>Claudia Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague 5</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kinder-und Jugendklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Neubert</last_name>
      <phone>004991318541237</phone>
      <email>Antje.neubert@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Rascher, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Meyer</last_name>
      <phone>00495115327848</phone>
      <email>meyer.nicol@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Dieter Haffner, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Pape, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Altalanos Orvostudomanyi Kar</name>
      <address>
        <city>Budapest</city>
        <state>Bokay Janos</state>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judit Horvath Turmezeine</last_name>
      <phone>003613343186</phone>
      <phone_ext>52633</phone_ext>
      <email>tuju@gyer1.sote.hu</email>
    </contact>
    <investigator>
      <last_name>Peter Sallay, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>De OEC Gyermekgyogyaszati Intezet</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inrene Banyasz</last_name>
      <email>tundebanyasz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tamas Sazbo, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Csaba Bereczki</last_name>
      <email>bereczki.csaba@med.u-szeged.hu</email>
    </contact>
    <investigator>
      <last_name>Sandor Turi, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Dzieciecy Szpital Kliniczny</name>
      <address>
        <city>Bialystok</city>
        <zip>15-274</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Smolko</last_name>
      <phone>0048857450823</phone>
      <email>gosia.smolko@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anna Wasilewska, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irena Blasz-Chmielewska, MD</last_name>
      <email>ibalasz@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Aleksandra Zurowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Dzieciecy w Krakowic</name>
      <address>
        <city>Krakow</city>
        <zip>30663</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Smolnik</last_name>
      <email>teresa.smolnik@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Zachwieja</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NZOZ tri-Medica</name>
      <address>
        <city>Lodz</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Krakowska</last_name>
      <email>annakrakowska@onet.pl</email>
    </contact>
    <investigator>
      <last_name>Marcin Tkaczyk, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dzieciecy Szpital Kliniczny Im</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Bienias</last_name>
      <email>beata.bienias@umlub.pl</email>
    </contact>
    <investigator>
      <last_name>Malgorzata Zajaczkowska, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny</name>
      <address>
        <city>Wroclaw</city>
        <zip>50556</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irena Makulska</last_name>
      <email>tundebanyasz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Danuta Zwolinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii Sf. Maria</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Urgenta pentru Copii - Louis Turcanu</name>
      <address>
        <city>Timisoara</city>
        <zip>300350</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children City Clinical Hospital of Saint Vladimir</name>
      <address>
        <city>Moscow</city>
        <zip>107014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budgetary Healthcare Institution &quot;Children City Hospital #1&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Instit. of Sverdlov Region &quot;Regional Children Clinical Hosp # 1&quot;</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cukurova University Faculty of Medicine Paediatric Nephrology</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Izmir Tepecik Training and Research Hospital</name>
      <address>
        <city>Izmir</city>
        <zip>4500</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inonu University Faculty of Medicine Department of Pediatric Health and Disease</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Manisa Celal Bayar University Hafsa Sultan Hospital</name>
      <address>
        <city>Manisa</city>
        <zip>45030</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
